| Calcium antagonists. Clinical use in the treatment of arrhythmias. | |
| | |
MedLine Citation:
|
PMID: 6339197 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Calcium antagonists have recently emerged as a class of drugs for the treatment of angina, hypertension and certain cardiac arrhythmias. Verapamil is the prototype calcium antagonist and has the most clearly defined antiarrhythmic properties. Other agents in the class include D-600 (gallopamil), tiapamil, nifedipine, and diltiazem. The antiarrhythmic effects of these compounds can be correlated with their electrophysiological properties which may differ significantly among different compounds and also between isolated tissues in intact animals and man. As a class they do not increase the effective refractory period of the atria, ventricle, His-Purkinje fibres or the accessory pathways in the heart. The dominant effect is slowing of conduction in the AV node with the prolongation of the AV nodal refractory period. The most marked changes are produced by verapamil, the least with nifedipine which is devoid of antiarrhythmic actions. Verapamil and its congeners as well as diltiazem terminate paroxysmal supraventricular tachycardia and slow the ventricular response in atrial flutter and fibrillation. They are also of prophylactic value in preventing recurrences of paroxysmal supraventricular tachycardia and controlling the ventricular response in atrial flutter and fibrillation during long term oral therapy. Their value in ventricular arrhythmias is uncertain but they are unlikely to be effective except in those complicating coronary artery spasms. The relative merits and potencies of various calcium antagonists in different arrhythmias need further studies. |
| | |
Authors:
|
B N Singh; K Nademanee; S H Baky |
Related Documents
:
|
10861707 - Early prenatal management of a fetal ventricular tachycardia treated in utero by amioda... 7127347 - Ventricular tachycardia during the first 72 hours after acute myocardial infarction. 14871247 - Cardiac monitoring of patients receiving arsenic trioxide therapy. 2659177 - Surgical treatment of arrhythmias in children. 2605547 - The choice of contrast agents in the cardiac catheterization laboratory. 16878707 - Clinical implication of reverse redistribution on 99mtc-sestamibi images for evaluating... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review |
Journal Detail:
|
Title: Drugs Volume: 25 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1983 Feb |
Date Detail:
|
Created Date: 1983-05-27 Completed Date: 1983-05-27 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: AUSTRALIA |
Other Details:
|
Languages: eng Pagination: 125-53 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Arrhythmia Agents Arrhythmias, Cardiac / drug therapy* Atrial Fibrillation / drug therapy Calcium Channel Blockers / adverse effects, pharmacology, therapeutic use* Death, Sudden / prevention & control Electrophysiology Heart Ventricles Humans Tachycardia, Paroxysmal / drug therapy Verapamil / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 0/Calcium Channel Blockers; 52-53-9/Verapamil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Calcium antagonists. Pharmacokinetic properties.
Next Document: Calcium antagonists. Clinical use in the treatment of systemic hypertension.